Results of Glucose-6-phosphate Dehydrogenase Deficiency Screening Relate with Cost of Phototherapy in Neonatal Hyperbilirubinemia; A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220705006

Enrollment

244

Registered

2022-07-05

Start date

2021-10-08

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) is one of risk factors that should decrease the phototherapy threshold to be lower than G6PD-normal neonates. hyperbilirubinemia, phototherapy, G6PD deficiency, neonate, screening

Interventions

Perform cord blood G6PD screening since birth ,Routine care which are assumed G6PD deficiency

Active Comparator Other,No Intervention Other

G6PD screening,Control

Eligibility

Sex/Gender

All

Age

1 Hours to 2 Days

Inclusion criteria

Inclusion criteria: 1. Neonates born at 35 or more weeks' gestation, 2. Born in Burapha University Hospital

Exclusion criteria

Exclusion criteria: Born before before obtain inform consent

Design outcomes

Primary

Measure	Time frame
Cost of phototherapy 14 days after birth Hospital cost	—

Secondary

Measure	Time frame
Incidence of G6PD deficiency 14 days after birth Cord blood G6PD screening	—

Countries

Thailand

Contacts

Public ContactSupamas Supabanpot

Faculty of Medicine, Burapha University

supamassup@gmail.com0814015512

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026